tiprankstipranks
Advertisement
Advertisement

ANTX Stock Latest News

AN2 Therapeutics Reprices Stock Options to Enhance Retention
Company AnnouncementsAN2 Therapeutics Reprices Stock Options to Enhance Retention
4d ago
8K
ANTX
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
7d ago
ANTX
AN2 Therapeutics Announces $40 Million Private Placement Financing
PremiumCompany Announcements
AN2 Therapeutics Announces $40 Million Private Placement Financing
14d ago
8K
ANTX
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
PremiumThe Fly
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
21d ago
ANTX
AN2 Therapeutics adjusts leadership roles and executive compensation
PremiumCompany Announcements
AN2 Therapeutics adjusts leadership roles and executive compensation
2M ago
8K
ANTX
AN2 Therapeutics announces FDA clearance of OSHU IND application
PremiumThe FlyAN2 Therapeutics announces FDA clearance of OSHU IND application
2M ago
ANTX
AN2 Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
AN2 Therapeutics Reports Q3 2025 Financial Results
4M ago
ANTX
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
Premium
The Fly
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
4M ago
ANTX
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
PremiumThe Fly
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
4M ago
GSK
ANTX
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
PremiumCompany Announcements
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
5M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
PremiumRatings
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
7M ago
ANTX
AN2 Therapeutics Reports Improved Financial Results
PremiumCompany Announcements
AN2 Therapeutics Reports Improved Financial Results
7M ago
ANTX
AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
PremiumThe FlyAN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
7M ago
ANTX
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
Premium
The Fly
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
7M ago
ANTX
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
Premium
The Fly
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
8M ago
ANTX
AN2 Therapeutics completes 200-patient observational study in acute melioidosis
PremiumThe Fly
AN2 Therapeutics completes 200-patient observational study in acute melioidosis
9M ago
ANTX
AN2 Therapeutics Enhances Financial Flexibility with Share Exchange
PremiumCompany Announcements
AN2 Therapeutics Enhances Financial Flexibility with Share Exchange
9M ago
8K
ANTX
AN2 Therapeutics Unveils Updated Investor Presentation
PremiumCompany Announcements
AN2 Therapeutics Unveils Updated Investor Presentation
10M ago
8K
ANTX
AN2 Therapeutics Elects New Directors at Annual Meeting
PremiumCompany Announcements
AN2 Therapeutics Elects New Directors at Annual Meeting
10M ago
8K
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
10M ago
ANTX
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
Premium
The Fly
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
11M ago
ANTX
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
Premium
The Fly
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
11M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >